biostudies-literatureUnknown8(39)Svobodova MIn this study, we describe the establishment of the human papillomavirus 18-positive, stage II, grade 1, T2N0M0 head and neck tumor primary cell line derived from oral squamous cell carcinoma of a non-smoking patient by using two different protocols. Furthermore, a preparation of subpopulations derived from this primary cell line according to the cluster of differentiation molecules CD44/CD90 status using magnetic bead-based separation and their characterization was performed. Impedance-based real-time cell analysis, enzyme-linked immunsorbant assay (ELISA), wound-healing assay, flow-cytometry, gene expression analysis, and MTT assay were used to characterize these four subpopulations (CD44⁺/CD90^-, CD44^-/CD90^-, CD44⁺/CD90⁺, Oncotarget66254-66269https://www.ebi.ac.uk/biostudies/studies/S-EPMC5630409biostudies-literatureEstablishment of oral squamous cell carcinoma cell line and magnetic bead-based isolation and characterization of its CD90/CD44 subpopulations.PMC5630409Balvan JPolanska HKostrica RHeger ZFojtu MSvobodova MRaudenska MGumulec JKratochvilova MMasarik MHorakova ZBabula PfalseEstablishment of oral squamous cell carcinoma cell line and magnetic bead-based isolation and characterization of its CD90/CD44 subpopulations.In this study, we describe the establishment of the human papillomavirus 18-positive, stage II, grade 1, T2N0M0 head and neck tumor primary cell line derived from oral squamous cell carcinoma of a non-smoking patient by using two different protocols. Furthermore, a preparation of subpopulations derived from this primary cell line according to the cluster of differentiation molecules CD44/CD90 status using magnetic bead-based separation and their characterization was performed. Impedance-based real-time cell analysis, enzyme-linked immunsorbant assay (ELISA), wound-healing assay, flow-cytometry, gene expression analysis, and MTT assay were used to characterize these four subpopulations (CD44⁺/CD90^-, CD44^-/CD90^-, CD44⁺/CD90⁺, 2017-01-01T00:00:00Z2017 Sep2026-07-16T13:25:30.158Z2019-03-27T02:58:23ZS-EPMC56304092902950910.18632/oncotarget.19914